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Prostate radiation therapy
rectal toxicity is largely due
to the prostate-rectum prox-
imity. A randomized,
controlled, multicenter study
of an absorbable poly-
ethylene glycol hydrogel
perirectal spacer (SpaceOAR
System) used in men under-
going image guided prostate
intensity modulated radiation
therapy was performed.
Spacer safety and effective-
ness in consistent perirectal
space creation and reduction
of rectal irradiation was
demonstrated. Spacer use
was associated with low
toxicity rates and a reduction
in patients experiencing de-
clines in bowel and urinary
quality of life.Purpose: Perirectal spacing, whereby biomaterials are placed between the prostate
and rectum, shows promise in reducing rectal dose during prostate cancer radiation
therapy. A prospective multicenter randomized controlled pivotal trial was performed
to assess outcomes following absorbable spacer (SpaceOAR system) implantation.
Methods and Materials: Overall, 222 patients with clinical stage T1 or T2 prostate
cancer underwent computed tomography (CT) and magnetic resonance imaging
(MRI) scans for treatment planning, followed with fiducial marker placement, and
were randomized to receive spacer injection or no injection (control). Patients received
postprocedure CT and MRI planning scans and underwent image guided intensity
modulated radiation therapy (79.2 Gy in 1.8-Gy fractions). Spacer safety and impact
on rectal irradiation, toxicity, and quality of life were assessed throughout 15 months.
Results: Spacer application was rated as “easy” or “very easy” 98.7% of the time,
with a 99% hydrogel placement success rate. Perirectal spaces were 12.6  3.9 mm
and 1.6  2.0 mm in the spacer and control groups, respectively. There were no
device-related adverse events, rectal perforations, serious bleeding, or infections
within either group. Pre-to postspacer plans had a significant reduction in mean rectal
V70 (12.4% to 3.3%, P<.0001). Overall acute rectal adverse event rates were similar
between groups, with fewer spacer patients experiencing rectal pain (PZ.02). A sig-
nificant reduction in late (3-15 months) rectal toxicity severity in the spacer group was
observed (PZ.04), with a 2.0% and 7.0% late rectal toxicity incidence in the spacer
and control groups, respectively. There was no late rectal toxicity greater than grade 1
in the spacer group. At 15 months 11.6% and 21.4% of spacer and control patients,
respectively, experienced 10-point declines in bowel quality of life. MRI scans at
12 months verified spacer absorption.
Conclusions: Spacer application was well tolerated. Increased perirectal space
reduced rectal irradiation, reduced rectal toxicity severity, and decreased rates of pa-
tients experiencing declines in bowel quality of life. The spacer appears to be an effec-
tive tool, potentially enabling advanced prostate RT protocols.  2015 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Radiation therapy (RT) is a well-established and widely
used treatment modality for prostate cancer, endorsed by
national guidelines (1), but implementation of hypo-
fractionation, dose escalation, and salvage RT protocols is
limited by the risk of rectal toxicity (2-4). As prostate-
rectum proximity contributes to this toxicity, there is
growing interest in perirectal spacing, whereby bio-
materials are used to push the rectum away from the
prostate to reduce rectal radiation exposure (5). A safe,
well-tolerated, and effective means of perirectal spacing
may enable dose escalation or hypofractionation protocols.
Several injectable agents including hyaluronic acid,
collagen, and polyethylene glycol hydrogels, along with an
implantable absorbable balloon have been evaluated as
spacing materials with encouraging results (6). Pilot studieshave demonstrated ease of spacer application, patient
tolerance, consistent rectal dose reduction, and good clin-
ical outcomes (7-10).
The most widely studied of these materials is a novel
polyethylene glycol hydrogel that expands the perirectal
space as an injected liquid and then polymerizes (solidifies)
into a soft, absorbable spacer (SpaceOAR system; Aug-
menix, Waltham, MA). The hydrogel spacer has been
shown to be stable throughout the typical course of radia-
tion therapy (11), resulting in a significant decrease in
rectal irradiation (12) and encouraging acute and late
outcomes (11).
This report describes the first prospective randomized
pivotal trial of a prostate-rectum spacer, investigating the
safety and effectiveness of this hydrogel in men under-
going prostate image guided intensity modulated RT
(IG-IMRT).
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Setting and patients
A multicenter randomized, controlled pivotal trial of the
hydrogel spacer was approved by the Institutional Review
Boards of each of the 20 participating centers under US
Food and Drug Administration-approved investigational
device exemption. All patients provided written informed
consent.
Men with stage T1 or T2 prostate cancer, a Gleason
score of 7, a prostate-specific antigen (PSA) concentra-
tion of 20 ng/mL, and a Zubrod performance status 0 to 1,
who were planning to undergo IG-IMRT were potential
study candidates. Exclusion criteria included a prostate
volume of >80 cm3, extracapsular extension of disease or
>50% positive biopsy cores, metastatic disease, indicated
or recent androgen deprivation therapy, and prior prostate
surgery or RT.
Study design
Two primary endpoints were defined. The primary effec-
tiveness endpoint was the proportion of patients achieving
>25% reduction in rectal volume receiving at least 70 Gy
(rV70) due to spacer placement. The 25% reduction was
deemed clinically relevant as it approximates the reduction
achieved when progressing from 3-dimensional conformal
RT to IMRT (13), and rV70 was selected due to published
correlations with the risk of late gastrointestinal toxicity
(14,15). The primary safety endpoint was the proportion of
spacer and control patients experiencing grade 1 or greater
rectal or procedural adverse events (AEs) in the first
6 months.
Patients underwent a physical examination, including
collection of medical and surgical history, baseline
concomitant medications, and a computed tomography
(CT) scan and magnetic resonance imaging (MRI) for
baseline IG-IMRT treatment planning. Using an aseptic
transperineal technique, we placed at least 3 gold intra-
prostate fiducial markers, and patients were immediately
randomized (envelope opened) to receive transperineal in-
jection of spacer (16) or no injection as a control. Patients
were blinded to randomization. Five to 10 days later, pa-
tients underwent a second CT and MRI for postprocedural
IG-IMRT treatment planning.
Clinical target volumes (CTVs) included prostate with
or without inclusion of the proximal seminal vesicles
(physician’s discretion). The planning methodology for
baseline and postprocedural plans was the same. The pre-
scription dose was 79.2 Gy at 1.8 Gy per fraction, delivered
to 98% of the planning target volume (PTV) and 100% of
the CTV, with the CTV maximum of 110% of the pre-
scription dose. PTV margins were institutionally deter-
mined within protocol-defined limits of 5 to 10 mm, and
normal rectal dose constraint objectives for 15%, 20%,25%, 35%, and 50% of the rectal volume were <75 Gy,
<70 Gy, <65 Gy, <60 Gy, and <50 Gy, respectively, per
quantitative analysis of normal tissue effects in the clinic
(QUANTEC) guidelines (17). All IG-IMRT planning
documentation and CT and MRI scans were forwarded to a
blinded, independent core laboratory (JM, HG, WB) for
verification of GTV, CTV, PTV, and critical normal struc-
tures (rectum, bladder, penile bulb) contours and dose-
volume histograms. The core laboratory verified all
dosimetric study data, measured the perirectal spaces
(distance between the posterior prostatic capsule and
anterior rectal wall on axial mid-gland T2-weighted MRIs)
at baseline and at 3 months, evaluated patients for hydrogel
placement success (hydrogel present in the perirectal
space), and assessed gel absorption using the 12-month
MRI (Fig. 1).
Patients were evaluated at baseline, weekly during
IG-IMRT, and at 3-, 6-, 12-, and 15-month follow-up visits
for rectal and other AEs and for changes in medications
used to treat urinary or rectal symptoms. All AEs were
recorded, and adjudication of event type, severity, event
cascading, and relatedness to device, procedure, radiation
or other was performed by an independent Clinical Events
Committee (CEC), blinded to treatment randomization.
Rectal and urinary AEs attributed by the CEC to radiation
were included for toxicity analysis according to National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0, when not attributed
to diet, medication, or medical history.
At baseline and 3, 6, 12, and 15 months, patients
completed the Expanded Prostate Cancer Index Composite
health-related quality of life (QOL) questionnaire. QOL
data were analyzed to determine the mean change in QOL
score from baseline to 15 months. In addition, the propor-
tion of patients experiencing declines in bowel and urinary
QOL from baseline was evaluated using previously deter-
mined 5- and 10-point thresholds for minimal clinically
detectable QOL changes (18).Statistical analysis
The accrual goal for this study was 222 patients (random-
ized spacer-to-control ratio of 2:1). For these sample sizes,
the power of the test for the primary effectiveness endpoint,
that at least 70% of the spacer patients would achieve a
25% reduction in rV70 was 99.4%. The power of the test
for the primary safety endpoint, assuming endpoint event
rates of 60% and 40% for the control and spacer groups,
respectively, was 80.8%. The overall probability that both
null hypotheses would be rejected was at least 80.2%.
Group demographic and cancer differences were deter-
mined using the two-sample t test for continuous variables
and the Fisher exact test for categorical data. The exact
binomial test was used to compare the proportion of spacer
patients experiencing a 25% rV70 dose reduction,
whereas the Cochran-Mantel-Haenszel test was used to
Table 1 Mean data for demographics and pretreatment
prostate cancer history
Attribute
Spacer
group
Control
group
P
value
Age (y) 66.4 67.7 .217
% racial distribution
White 85.2 83.6 .843
African American 10.7 11.0 1.000
Asian 1.3 2.7 .600
Other 2.8 2.7 1.000
Weight (kg) 88.8 90.1 .551
Height (cm) 176.1 176.3 .817
BMI (kg/m2) 28.6 29.0 .608
% with smoking history .931
Current smoker 8.1 9.6
Past smoker 51.7 50.7
Never smoked 40.3 39.7
Prostate volume (mL) 47.3 49.6 .286
Number of biopsy cores 12.6 12.3 .369
% of positive biopsy cores 23.1 23.0 .942
% with combined Gleason
score of:
.059
6 64.4 50.7
7 35.6 49.3
% with T stages shown .549
T1 (T1, T1a, T1b, T1c) 63.8 68.5
T2 (T2, T2a, T2b, T2c) 36.2 31.5
Pretreatment PSA (ng/mL) 5.6 5.7 .813
Palpable tumor (%) 23.0 24.7 .537
Abbreviations: BMI Z body mass index; PSA Z prostate-specific
antigen.
Fig. 1. T2-weighted magnetic resonance images of a spacer patient at baseline (a), post-application (b), and 12 months
after spacer application (c).
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patients experiencing declines in QOL were determined
using the c2 test. Statistical analysis was performed using
SAS version 9.1.3 software. All statistical tests were per-
formed at a significance level of .05.
Results
Between January 2012 and April 2013, 149 and 73 patients
were randomized to the spacer and control groups,
respectively. Strict protocol adherence resulted in 219 of
222 (98.5%) patient follow-up through completion of study
at 15 months. There were no differences between groups in
regard to medical comorbidities, demographics, or baseline
tumor characteristics, as detailed in Table 1.
In the study, antibiotic prophylaxis was administered
prior to fiducial or fiducial and spacer procedure 95% of the
time, whereas forms of anesthesia and sedation included
general (36.4%), local (31.4%), monitored anesthesia care
(25.5%), conscious sedation (5.5%), and other (10.5%).
Both the radiation oncologists and urologists who applied
the spacer rated the device’s ease of use as “easy” or “very
easy” 98.7% of the time. The hydrogel placement success
in the spacer group was 98.7%.
The mean perirectal distance in the spacer group was
1.6  2.2 mm, 12.6  3.9 mm, and 9.0  5.9 mm at
baseline, postspacer application, and at 3 months
(1 week), respectively. Hydrogel absorption was evident
during the 3-month imaging, with the mean space in pa-
tients imaged the week prior to their 3-month date being
10.9  5.8 mm, compared to 6.8  5.4 mm for those
imaged the week after. T2-weighted MRI at 12 months
confirmed spacer absorption, with 3 (2%) of the spacer
patients exhibiting small, simple water density remnant
cysts in otherwise unremarkable perirectal tissues.
The core laboratory-measured spacer group rectal dose
reduction (Table 2), calculated by comparing the baseline
to postprocedure rectal DVH, was statistically significant
(P<.0001) from rV50 through rV80. The mean spacer andcontrol group rV70s at baseline were 12.4% and 12.4%
(PZ.95), respectively, and in the postprocedure treatment
plans were 3.3% and 11.7% (P<.0001), respectively.
Overall, 97.3% of spacer patients experienced a 25%
reduction in rV70, resulting in attainment of the primary
effectiveness endpoint. Additionally, 100% and 92% of
spacer and control patient plans met all rectal dose con-
straints, respectively.
Table 2 Mean  SD spacer group rectal dose volume his-
togram data comparing baseline to post-spacer dose plans*
Parameter rV50 rV60 rV70 rV80
% before
spacer
25.7  11.1 18.4  7.7 12.4  5.4 4.6  3.1
% after spacer 12.2  8.7 6.8  5.5 3.3  3.2 0.6  0.9
% of absolute
reduction
13.442 11.563 9.078 3.933
% of relative
reduction
52.3 62.9 73.3 86.3
P value <.0001 <.0001 <.0001 <.0001
Abbreviation: rV Z reduction in rectal volume dose of, eg, 50 Gy.
* Also listed are absolute percentage of reductions and relative re-
ductions of dose volume histogram means.
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boring tissues, with the mean pre- and postapplication
spacer group bladder V70 being 11.3% and 11.0%. The
mean penile bulb dose was less in the spacer group
(18.0 Gy) than in the control group (22.8 Gy, PZ.036).
Regarding the primary safety endpoint, the rates of
grade 1 or greater rectal or procedure AEs in the first
6 months were 34.2% and 31.5% in the spacer and control
groups (PZ.7), respectively. Mild transient procedural AEs
(perineal discomfort and others) were noted in 10% of the
spacer patients, contributing to this overall rate. Aside from
a reduction in the rate of patients with acute rectal pain AEs
during RT (spacer: 2.7%; control: 11.1%, PZ.022), dif-
ferences in all other rectal or urinary acute AEs were not
statistically significant.
As with AEs in the first 6 months, no differences in
acute rectal or urinary toxicity in the first 3 months were
observed (Table 3). Late rectal toxicity (3-15 months) was
observed in 2.0% of the spacer patients (1 grade 1 rectal
bleeding, 1 grade 1 rectal urgency, and 1 grade 1 proctitis)
and 7.0% of the control patients (3 grade 1 rectal bleeding,
1 grade 1 rectal urgency, and 1 grade 3 proctitis). TheTable 3 Acute and Late rectal and urinary toxicity*
Grade
Acute toxicity (from pr
Rectal toxicity scores (%)
P valueSpacer (nZ148) Control (nZ72)
0 108 (73.0%) 49 (68.0%) .525
1 34 (23.0%) 20 (27.8%)
>2 6 (4.1%)y 3 (4.2%)z
Grade Late toxicity (between the third and 15th month visits)
Spacer (nZ148) Control (nZ71) P value
0 145 (98.0%) 66 (93.0%) .044
1 3 (2.0%) 4 (5.6%)
>2 0 (0.0%) 1 (1.4%)z
* According to Common Terminology Criteria for Adverse Events scoring
y No grade 3 or 4 toxicity reported.
z One grade 3 case; no grade 4 reported.spacer group reduction in late rectal toxicity severity was
statistically significant (PZ.044), with no spacer patients
experiencing grade >1 late rectal toxicity.
Mean changes in bowel and urinary QOL domains for
both the spacer (7.5 and 11.5) and the control groups
(6.2 and 11.2), respectively, at 3 months were small
relative to those cited in published reports, with no sta-
tistical significance between groups and a return to near
baseline QOL at 6 months. However, an appreciable
percentage of patients experienced persistent declines in
bowel QOL from baseline after 3 months. At 3 months, a
similar percentage of spacer and control patients experi-
enced 5- and 10-point declines in bowel QOL (Fig. 2). At
6, 12, and 15 months, a lower proportion of spacer pa-
tients reported declines in bowel QOL relative to those of
control, with 11.6% and 21.4% of spacer and control
patients, respectively, experiencing 10-point declines at
15 months (PZ.087). Additionally, at 6 months, 8.8% and
22.2% of spacer and control patients, respectively,
had 10-point urinary declines (PZ.003). At 12 and
15 months, the declines in urinary QOL were similar for
both groups.
Overall, the rates of AEs and serious AEs for the spacer
(96.6% and 13.4%, respectively) and control (100% and
15.1%, respectively) groups were not significantly
different. The CEC blinded adjudication of all recorded
AEs found no spacer-related AEs. The proportion of pa-
tients requiring at least 1 medication change for mitigation
of rectal or urinary symptoms in the first 6 months was
56.4% and 63.9% for spacer and control groups, respec-
tively (PZ.3102). There were no differences in PSA values
of the spacer and control groups at 12 months (1.257 ng/mL
and 1.309 ng/mL, PZ.968, respectively) and 15 months
(1.135 ng/mL and 1.073 ng/mL, respectively, PZ.787). No
subjects experienced a delay in RT associated with a pro-
cedure or device-related AE. There were no rectal perfo-
rations, serious rectal bleeding, or rectal infections in either
group.ocedure through 3-month visit)
Urinary toxicity scores (%)
P valueSpacer (nZ148) Control (nZ72)
14 (9.5%) 7 (9.7%) .488
78 (52.7%) 33 (45.8%)
56 (37.8%)y 32 (44.4%)y
Spacer (nZ148) Control (nZ71) P value
134 (90.5%) 65 (91.5%) .622
4 (2.7%) 3 (4.2%)
10 (6.8%)y 3 (4.2%)y
of adverse events attributed to radiation.
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Fig. 2. Percentage of patients with 5- and 10-point de-
clines in bowel (top) and urinary (bottom) quality of life
(QOL).
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Spacer appliers found the procedure to be straightforward,
with a high hydrogel placement success rate. Application
resulted in an average of 12.6 mm of perirectal space.
Hydrogel remained in place for 3 months, with absorption
confirmed at 12 months.
Hydrogel application significantly reduced rectal irra-
diation from rV50 to rV80 relative to both the control and
prespacer plans. Additionally, dose reduction was consis-
tent, with 97.3% of spacer patients achieving 25%
reduction in rV70. Spacer application did not result in
higher dose elsewhere, as seen in bladder dosimetry.
Finally, achievement of rectal dose constraints appeared
easier in the spacer group, with 100% of patients meeting
all constraints.
Even though the spacer group did not have fewer rectal
or procedural AEs than the control group in the first
6 months, the similar AE rate demonstrates that spacer use
does not create new safety issues. The statistically signifi-
cant reduction in acute rectal pain AEs in spacer patients is
supported by a bowel domain QOL question on rectal pain
(painful stools half or more of the time) at 6 months (0%
and 5.6%, P<.05) and 12 months (0% and 4.2%, P<.05) for
the spacer and control groups, respectively.
Late rectal toxicity in the spacer group was significantly
less severe than in the control group (PZ.044), with no
spacer patients experiencing grade >1 late rectal toxicity.
Of note, this is the second clinical evaluation of this spacer
product showing no late rectal toxicity grade >1. Also of
interest is the low control group toxicity rate (11). The most
likely explanations for the low control toxicity rate includeuniform IGRT use and core laboratory review and approval
of treatment plans. Arguably, this study-mandated forced
precision planning led to low toxicity in the control group
relative to that in standard practice.
Compared to previous studies, the decline in bowel and
urinary QOL in both groups was very modest. Although the
time points are not the same, the PROSTQA study (external
beam RT, 75-79.2 Gy in 1.8- to 2.0-Gy fractions) com-
parison is most relevant (19). At 2 and 24 months, the
PROSTQA study reported QOL changes (bowel: 16.0%,
7.0%; urinary: 12.2%, 0.2%), compared to declines at 3
and 15 months for the spacer group (bowel: 7.5% and
0.02%; urinary: 11.5% and 1.9%) and control (bowel:
6.2%, 2.1%; urinary: 11.2%, 2.5%), respectively.
Similar proportions of spacer and control group patients
experienced 5- and 10-point declines from baseline in
bowel and urinary QOL at 3 months. At 6, 12, and
15 months, the spacer group had a lower percentage of
patients with declines in bowel QOL, in agreement with the
decreased late rectal toxicity data. The reason why fewer
spacer patients had declines in urinary QOL at 6 months is
unknown.
Conclusions
Overall safety of the spacer seemed to be excellent, with no
device-related AEs and no rectal infections, rectal com-
plications, and other AEs. Creation of perirectal space was
consistent in spacer randomized patients, with a high
hydrogel placement success rate and resulting in a clini-
cally significant reduction in rectal irradiation in almost all
patients. The low spacer group late toxicity and favorable
bowel QOL results are expected outcomes from reduced
rectal irradiation.
The short follow-up period is a study limitation, as re-
searchers have published the median time to late gastroin-
testinal grade >2 toxicity onset was 17 months (20). The
study was also limited by the exclusion of patients with
prostate volumes >80 mL, patients with extracapsular
extension, and those with prior radiation or surgery. Pa-
tients with extracapsular extension have the theoretical risk
of pushing posterior extracapsular disease farther from the
prostate during RT, whereas patients with prior radiation or
surgery may have perirectal scar formation, limiting space
creation. Use of spacers in these populations should pro-
ceed cautiously in separate clinical trials.
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